Even as it’s moving into the US tobacco alternatives market, Philip Morris International (PMI) may be setting itself up for a future move into the cannabis industry. The company has reportedly purchased a patent for a genetically modified cannabis plant, and is said to have invested $20m in an Israeli company that makes cannabis inhalers.
Meanwhile, an expert on cannabis and behaviour has told ECigIntelligence that reports of 60 people suffering medical ill-effects from vaping products marketed as containing cannabinoid oil suggested symptoms consistent with them having received “tainted product”.
Sign up to access to our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
